INTEGRA LIFESCIENCES HOLDINGS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.28 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-29
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $10.77, a 31.31% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $15.68, a 27.34% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $21.58, a 6.78% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $23.15, a 2.48% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $10.77, a 31.31% decline from fiscal 2024.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $15.68, a 27.34% decline from fiscal 2023.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $21.58, a 6.78% decline from fiscal 2022.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $23.15, a 2.48% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.28 10-Q · filed 2026-07-29 | ||||
| 2025-12-31 | $10.77 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $10.77 10-Q · filed 2025-10-30 | ||||
| 2025-06-30 | $10.77 10-Q · filed 2025-07-31 | ||||
| 2025-03-31 | $10.77 10-Q · filed 2025-05-05 | ||||
| 2024-12-31 | $15.68 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $15.68 10-Q · filed 2024-11-04 | ||||
| 2024-06-30 | $15.68 10-Q · filed 2024-07-29 | ||||
| 2024-03-31 | $15.68 10-Q · filed 2024-05-06 | ||||
| 2023-12-31 | $21.58 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $21.58 10-Q · filed 2023-10-25 | ||||
| 2023-06-30 | $21.58 10-Q · filed 2023-07-27 | ||||
| 2023-03-31 | $21.58 10-Q · filed 2023-04-26 | ||||
| 2022-12-31 | $23.15 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $23.15 10-Q · filed 2022-10-26 | ||||
| 2022-06-30 | $23.15 10-Q · filed 2022-07-27 | ||||
| 2022-03-31 | $23.15 10-Q · filed 2022-04-27 | ||||
| 2021-12-31 | $22.59 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $22.59 10-Q · filed 2021-11-02 | ||||
| 2021-06-30 | $22.59 10-Q · filed 2021-07-29 | ||||
| 2021-03-31 | $22.59 10-Q · filed 2021-04-29 | ||||
| 2020-12-31 | $13.03 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $13.03 10-Q · filed 2020-10-29 | ||||
| 2020-06-30 | $13.03 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $13.03 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $18.74 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $18.74 10-Q · filed 2019-10-25 | ||||
| 2019-03-31 | $18.74 10-Q · filed 2019-07-25 | ||||
| 2018-12-31 | $21.78 10-K · filed 2021-02-23 | ||||
| 2017-12-31 | $16.95 10-K · filed 2020-02-21 | ||||
| 2016-12-31 | $12.48 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $8.59 10-K · filed 2018-03-01 | $17.17 10-K · filed 2016-02-26 | |||
| 2014-12-31 | $9.08 10-K · filed 2017-02-23 | $18.15 10-K · filed 2015-02-27 | |||
| 2013-12-31 | $13.86 10-K · filed 2016-02-26 | ||||
| 2012-12-31 | $12.18 10-K · filed 2015-02-27 | ||||
| 2011-12-31 | $19.18 8-K · filed 2014-06-20 | ||||
| 2010-12-31 | $17.03 10-K · filed 2013-02-26 | ||||
| 2009-12-31 | $8.12 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |